Celgene (CELG) Presents Results from Three CC-486 Studies in MDS, CMML, and AML at ASH 2016
Tweet Send to a Friend
Celgene Corporation (Nasdaq: CELG) announced results from an analysis of three phase I/II studies evaluating CC-486 in patients with myelodysplastic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
